期刊文献+

^(131)I-Herceptin的血液存在方式及体内外稳定性研究 被引量:1

In vivo and in vitro stability of ^(131)I-Herceptin and its form of existence in the blood of rabbits
下载PDF
导出
摘要 目的探讨131I-Herceptin的稳定性与生物学特性。方法 131I-Herceptin采用Iodogen法制备,其基础放射化学纯度(RCP)为(94.9±2.7)%。4℃冰箱内放置3、24、48、72、96h,取各时间样品测RCP。取家兔5只,静脉注射131I-Herceptin后1h、3h、6h、24h、2d、3d、4d、5d取血,分离血清及血细胞,测血清131I-Herceptin的RCP,并测定血清或血细胞放射性计数百分比。各组样品RCP的差异分析采用One-way Anova检验。结果 4℃放置72h以内,RCP未见显著下降(F=15.985,P<0.001);72h后显著(t=9.971,P<0.001)下降至(82.6±2.8)%。注射后1~96h,131I-Herceptin主要存在于血清,其放射性所占比例稳定在81%~87%。注射体内后1h,血清内131I-Herceptin的RCP为(90.9±8.5)%,未见显著差异(t=1.753,P>0.05)。24h后为(75.4±3.9)%,提示开始显著降低(t=6.564,P<0.001)。结论采用Iodogen法标记的131I-Herceptin,体外放置72h内,放射化学纯度基本稳定,注入体内后主要存在于血清,24h以内放射化学纯度稳定,24h后降解明显。 Objective To evluate the in vivo and in vitro stability of 131I-Herceptin and its form of existence in the blood.Methods Herceptin was labelled with iodine-131 using the Iodogen method.131I-Herceptin was stored at 4 ℃ for 3,24,48,72 and 96 h,and the radiochemical purity(RCP) was measured by high performance liquid chromatography(HPLC).Five rabbits received injections of 131I-Herceptin and at 1,3,6,24,48,72,96 and 120 h after the injection,blood samples were taken to measure the RCP of 131I-Herceptin in the serum,and the radiocount of the serum and blood cells was calculated.Results The baseline RCP of 131I-Herceptin was(94.9±2.7)%.The RCP was stable after placement at 4 ℃ for not over 72 h(F=15.985,P 〈0.001),but was significantly lowered to(82.6±2.8)% after preservation for over 72 h(t=9.971,P〈0.001).Within the time of 1.0 to 96 h after injection in rabbits,131I-Herceptin exsited mainly in the serum with a radiocount of 81%-87%;24 h after the injection,the RCP of 131I-Herceptin in the serum was significantly lowered to(75.4±3.9)%(t=6.564,P〈0.001).Conclusion Storage at 4 ℃ for no more than 72 h does not obviously affect the activity of 131I-Herceptin in terms of RCP.After injection in rabbits,131I-Herceptin exsits mainly in the serum and its radiochemical purity remains stable within 24 h,after which obvious degradation occurs.
出处 《南方医科大学学报》 CAS CSCD 北大核心 2010年第11期2463-2465,共3页 Journal of Southern Medical University
基金 广东省自然科学基金(037050)~~
关键词 抗体 单克隆 碘放射性同位素 HERCEPTIN 代谢 antiboby monoclonal iodine radioactive isotope herceptin metabolism
  • 相关文献

参考文献9

二级参考文献38

  • 1王建,纪渤,杨志,余振梅,唐采白,郭召军,于世良.抗CEA人/鼠嵌合抗体rch24在裸鼠人结肠癌模型中的放射免疫显像[J].中华核医学杂志,2005,25(1):51-51. 被引量:1
  • 2罗朝学,程绍钧,李前伟.HepG_2人肝癌细胞胰岛素样生长因子1受体定量分析[J].第三军医大学学报,2005,27(3):206-208. 被引量:5
  • 3邵文博,韩建奎,宋金龙,丛宁.^(125)Ⅰ粒子植入治疗荷人肝癌裸鼠移植瘤的实验研究[J].中华核医学杂志,2006,26(1):23-25. 被引量:12
  • 4任均田,李峰,谢春霖,迟文.Iodogen法碘标记McAb技术探讨[J].放射免疫学杂志,1996,9(3):145-146. 被引量:4
  • 5Britten CD, Finn RS, Bosserman LD, et al. A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approach. Clin Breast Cancer, 2009, 9: 16-22.
  • 6Chert MH. Cardiac dysfunction induced by novel targeted anticancer therapy: an emerging issue. Curr Cardiol Rep, 2009, 11: 167- 174.
  • 7Fornier MN. Epothilones in breast cancer: review of clinical experience. Ann Oncol, 2007,18 Suppl 5 : v16-21.
  • 8Palmedo H, Bucerius J. Radionuclide therapy in oncology: repeated administrations of high dose rate radiopharmaceuticals. Eur J Nucl Med Mol Imaging, 2004, 31: 1556-1559.
  • 9Li G, Wang Y, Huang K, et al. The experimental study on the radioimmunotherapy of the nasopharyngeal carcinoma overexpressing HER2/neu in nude mice model with intratumoral injection of ^188Re-herceptin. Nucl Med Biol, 2005, 32: 59-65.
  • 10Conti F, Vici P. Vinorelbin in the treatment of breast cancer: current status and prospectives for the future[J]. Clin Ther, 1998, 149(921): 61-74.

共引文献17

同被引文献4

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部